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1 Zanapezil (TAK-147 (3-[1benzylpiperdin-4-yl]-1-(2,3,4,5-tetrahydro-1 H-1-benzazepin-8-yl) pro-
pan-1-one fumarate)) is a selective acetylcholine (ACh) esterase inhibitor under investigation as a drug
for Alzheimer’s disease (AD) treatment.
2 In this study, the effects of TAK-147 at 2mgkg1 p.o. for 21 days, compared to donepezil (E2020),
on the levels of ACh, catecolamines and indoleamines were investigated in the ventral hippocampus
(VH) of freely moving rats by microdialysis-high-performance liquid chromatography.
3 The results revealed that the VH contains 92.05721.97 fmol 20ml1 ACh and the following
monoamines levels (pg 30 ml1), norepinephrine (NE) 1.9270.39, epinephrine (Epi) 1.9170.183, 3-
methoxy-4-hydroxyphenylglycol (MHPG) 11.5373.22, normetanephrine 3.2670.61, dopamine (DA)
0.7770.23, 3,4-dihydroxyphenylacetic acid (DOPAC) 3.3771.01, homovanillic acid (4-hydroxy-3-
methoxyphenylacetic acid; HVA) 4.0470.93, 3-methoxytyramine 0.6470.13, serotonin (5-HT)
0.7370.16 and 5-hydroxyindoleacetic acid (5-HIAA) 313.15718.42.
4 On the 21st day and prior to the last dose, TAK-147 increased ACh, Epi, DA and 5-HT, whereas
E2020 increased MHPG, Epi and DA. Following the last dose, TAK-147 increased NE, whereas
E2020 increased NE, ACh and 5-HT in addition to their effects prior to the last dose. TAK-147
decreased HVA :DA ratio, but only marginally decreased DOPAC :DA and 5-HIAA : 5-HT ratios.
On the other hand, E2020 decreased ratios of HVA :DA, DOPAC :DA (prior to the last dose), and
5-HIAA : 5-HT (90–180min after the last dose). Both drugs decreased MHPG :NE only at 180min
after the last dose. The results also showed that TAK-147 increased Epi :NE ratio prior to and for
120min following the last dose, whereas E2020 increased the ratio only before the last dose. The
present results show that TAK-147 at a subthreshold dose could differentially increase ACh and
5-HT, compared to MHPG increased by E2020. The last dose of each drug could extend their effects
to other monoamines.
5 The increase of the monoamines levels, in addition to that on the ACh, and decrease of their
oxidation could be of value in the treatment of the AD, other dementic diseases and the cohort
neurological disorders depending on the type of the monoamine underlying the disorder.
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Introduction
Zanapezil (TAK-147 (3-[1benzylpiperdin-4-yl]-1-(2,3,4,5-tetra-
hydro-1 H-1-benzazepin-8-yl) propan-1-one fumarate)) has
been introduced into Alzheimer’s disease (AD) treatment as a
novel, potent, reversible and selective acetylcholine (ACh)
esterase (AChE) inhibitor (AChEI) with brain/plasma con-
centration ratio of 7.0–20.6 (Kosasa et al., 2000) and lesser
(compared to donepezil, E2020) peripheral and central side
effects (Hatip-Al-Khatib et al., 2004) or even without
producing peripheral side effects (Ishihara et al., 2000).
Additionally, TAK-147 has been shown to inhibit moderately
muscarinic M1 and M2 receptor binding, but with very weak
or no inhibition of high-affinity choline ([2-hydroxyethyl]
trimethylammonium) uptake or binding to nicotinic receptor
(Hirai et al., 1997). Moreover, TAK-147 increases cerebral
energy metabolism (Nakayama et al., 1996; Ishihara et al.,
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2000), improves hippocampal metabolic activity (Xu et al.,
2002) and, like E2020, enhances the choline acetyltransferase
activity more potently than tacrine (Kato et al., 1999).
Furthermore, TAK-147, at AChE inhibiting dose, is reported
to provide NGF-like neurotrophic activity on central choli-
nergic neurons not only via AChE inhibition but also possibly
via an effect on tau receptors (Kato et al., 1999; Ishihara et al.,
2000). Behaviorally, TAK-147 ameliorates the passive avoid-
ance deficit induced by diazepam and the impairment of
delayed-matching-to-position performance induced by scopol-
amine without affecting the general behavior of the rats,
and reverses reserpine-induced hypothermia and ptosis in
mice (Miyamoto et al., 1996). Moreover, TAK-147 improves
memory impairment in the passive avoidance test and Morris
water maze induced by scopolamine (Ishihara et al., 2000;
Chen et al., 2002), provides neuroprotection and ameliorates
ischemia-induced memory deficits (Xu et al., 2002).
E2020 is an other potent, selective and reversible central
AChEI (Kosasa et al., 2000; Ogura et al., 2000; 2001; Isoma
et al., 2002). E2020 is used in the treatment of AD, where it has
been reported to provide significant improvements in cogni-
tion and the global function (Wilkinson et al., 2003). It has
been reported that chronic treatment with E2020 at 0.1–
2mgkg1 for 14 days could extend long-term potentiation
decay times at the perforant path-granule cell synapse, and
elevate the number of nicotinic receptors within the hippo-
campus and neocortex of aged rats (Barnes et al., 2000). In rat,
E2020 increases hippocampal blood flow (Hatip-Al-Khatib
et al., 2004). In the AD patients receiving chronic (1172.6
months) treatment at 5mgday1, E2020 preserves brain
perfusion (Nobili et al., 2002). Additionally, it has been
reported that E2020 at 5mg given every morning for 7 days
could improve sedation and fatigue in patients receiving
opioids for cancer pain (Bruera et al., 2003). Moreover,
treatment with E2020 at 10mg day1 for 1 month dramatically
improves sensorimotor function in the hemiplegic lower limb
and shoulder (Berthier et al., 2003). Experimentally, E2020
improves learning impairments in some hypocholinergic
models in rats (Ogura et al., 2001; Balducci et al., 2003;
Misane & Ogren, 2003) and in patients with traumatic brain
injury (Morey et al., 2003). Acute and chronic administration
of E2020 (0.1mgkg1 for 7 or 14 days) significantly reduces
the selective serotonin, 5-HT(2A/2C) agonist 1-(2, 5-di-
methoxy-4-iodophenyl)-2-aminopropane-induced head twitch
response (Hayslett & Tizabi, 2003).
In spite of the fact that treatment of the AD requires chronic
drug therapy, most of the experimental studies on the relevant
drugs had been conducted using acute administration of a wide
range of doses. Previous studies had dealt with acute effects of
TAK-147 and E2020 on ACh, of effects of E2020 on dopamine
(DA), norepinephrine (NE) and 5-HT, and of chronic effects
of E2020 on ACh. In a single-dose study (Hatip-Al-Khatib
et al., 2004), we have determined the ED50 value of 4.52
and 4.07mgkg1 for TAK-147 and E2020, respectively,
and the threshold dose of 5mg kg1 p.o. for the ACh-
increasing effect of both drugs in the ventral hippocampus
(VH). No comparative study of TAK-147 and E2020 or of
chronic effects of TAK-147 on ACh and DA, NE and 5-HT,
and of E2020 on DA, NE and 5-HT are available in the
literature. Accordingly, the present study aimed at determining
the effect of the subthreshold dose of TAK-147 administered
p.o. for 21 days on the ACh and monoamines levels and their
metabolites in the VH. The effect of TAK-147 was compared
to E2020.
Methods
Animals
The experiments were performed on 7-week-old (220–230 g)
male Wistar rats (Kyudo Co., Saga, Japan). The rats were
housed in groups of five per Plexiglas cage (42 26 15 cm)
under standard conditions of temperature (21–241C), humidity
(40–60%) and 12 h light : dark cycle with light period starting
at 07:00. Food and water were available ad lib. After arrival of
the rats and before the experiments, 1 week was allowed. The
experiments were carried out in compliance with the guidelines
of Fukuoka University. The body weights were recorded daily.
While the groups were homogeneous without intergroup
differences, the control (0.5% methylcellulose, MC), TAK-
147 and E2020 groups exhibited significant (Po0.01) 16, 20
and 12% increments, respectively, on day 21 compared to the
pretreatments.
Stereotaxic procedure
The rats were anesthetized with sodium pentobarbital
(50mg kg1 intraperitoneally (i.p.); Tokyo Kasei, Tokyo,
Japan) and placed in a stereotaxic frame (Narishige Scientific
Instruments Lab., Tokyo, Japan). Guide cannulae (13mm
long, i.d. 0.75mm, o.d. 0.85mm, Eicom, Kyoto, Japan) were
implanted into the VH according to Paxinos & Watson (1998).
The coordinates (mm), relative to skull surface with the upper
incisor bar 3.4mm below the level of interaural line, were:
posterior to bregma, AP¼4.8; lateral from midsagittal line,
L¼ 5; and dorsoventral, DV¼ 6. Body temperature was
maintained using a heating pad and a lamp during the surgery
and upon recovery from anesthesia. The implanted cannulae
were then secured with dummy cannulae kept in place by a
cap. After surgery, each rat was injected with penicillin in
hindquarter muscle (100,000U) and housed singly after
operation.
Microdialysis procedures
The extracellular levels of ACh and monoamines were
measured in the VH by microdialysis technique, at least 3
days after surgery, in unanesthetized freely moving rats. The
microdialysis probes were 13mm long (i.d. 0.5mm, o.d.
0.6mm; Eicom) with an active dialysis membrane exposed at
the tip. The dialysis membrane was U-shaped tube (each arm
3mm long, i.d. 0.22mm, o.d. 0.24mm, total length of both
arms 6–7mm) made of cellulose hollow fiber with a molecular
weight cutoff value 50 kDa. The Ringer-primed probes were
implanted through the guide cannulae with the U-shaped
dialysis membrane parallel to the longitudinal axis of the
brain, and protruded 3mm into the VH through the tip of the
guide cannulae and secured by caps. The rats were then placed
in a Plexiglas chamber (50 35 35 cm). The inlet of the probe
was connected to the descending limb of spiral two-way
tubing, which was in turn connected via pair-ring swivel system
to another Teflon tube connected to microsyringes driven by
micro syringe pump (SP-64, Eicom). The outlet of the probe
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was connected to the ascending limb of the swivel that was
connected by another Teflon tube to an autoinjector (EAS-20,
Eicom). The tubes and each limb of the spiral two-way tubing
were 0.1 (i.d.) 0.4 (o.d.)mm 50 cm long Teflon tubes
(Eicom). The implanted probe was perfused for 3 h with
Ringer’s solution (NaCl 147.0mM, KCl 4.0mM, CaCl2 . 2H2O
2.2mM), free from any AChEI, at a flow rate of 1 ml min1.
Dialysate aliquots were collected every 20min (20 ml, ACh) or
30min (30 ml, monoamines) and directly injected into high-
performance liquid chromatography (HPLC) system and
assayed for ACh or monoamines. After a settling period (at
least 2–3 h), three samples were collected in basal conditions.
The rats were then challenged with each treatment and
aliquots were then collected for the following 120min (ACh)
or 180min (monoamines).
Determination of extracellular ACh and monoamines
(catecholamines and indolamines) levels
The levels of ACh in the dialysates were assayed directly by
HPLC method (EP-300 Liquid chromatography, Eicom). ACh
was separated on a reverse-phase analytical column (Eicompak
AC-GEL, 2.0+ 150mm; Eicom). A guard (pre) column
(3.0+ 4mm with CH-GEL filter; Eicom) was placed before
the analytical column outside the HPLC. An enzyme column
(AC-ENZYMPAK, 3.0mm +; Eicom) in which AChE and
choline oxidase are immobilized on controlled-pore glass
(546 Å diameter of pore and 200/400 mesh glass beads) was
placed after the analytical column inside the HPLC. Following
its separation on the analytical column, ACh was hydrolyzed
by AChE to acetate and choline in a postcolumn enzyme
reactor, and choline was oxidized by choline oxidase to
produce betaine and hydrogen peroxide. The analytical and
enzyme columns were maintained at 331C by a column oven
(ATC-300, Eicom). Detection was performed using an
electrochemical detector (ECD-300, Eicom) with a platinum
electrode (WE-PT) set at þ 450mV vs Ag/AgCl reference
electrode (Ag/AgCl RE-100). The mobile phase (Na2H-
PO4 . 12H2O 50mM, H3PO4 50mM, sodium 1-decanesulfonate
1.23mM and EDTA 2Na 0.013mM, pH 8.2) was degassed
(DG-300, Eicom) and pumped at a flow rate 0.15mlmin1. An
internal standard (isopropylhemicholine 0.05 pg ml1) was
injected into the autoinjector at a rate of 1ml min1 simulta-
neously with the perfusion Ringer solution. Preliminary
studies revealed that 106M tetrodotoxine decreased the
release of ACh (80%) and DA (90%). The level of ACh
decreased in calcium-free perfusing Ringer by 60%. Pargyline
increased DA and 5-HT by 150 and 350%, respectively (data
not shown).
The levels of catecholamines and indolamines were deter-
mined as mentioned above, except that the analysis conditions
were as follows: column – EICOMPAK SC-50 ODS
+3.0mm 150mm; precolumn – PREPAK +4.0mm
5.0mm; ECD þ 750mV against Ag/AgCl reference electrode;
and oven temperature 251C. The mobile phase contained 0.1M
acetate-citrate buffer (pH 3.5), 190mg l1 sodium 1-octane-
sulfonate, 5mg l1 EDTA and 16% methanol, degassed and
pumped at a flow rate 0.25mlmin1.
The peaks were recorded using Powerchrom integrator
(Eicom). To evaluate the amount of ACh and monoamines in
the samples, a linear regression curve was constructed for the
standards (1 pmol of choline, isopropylhemicholine and ACh
standards for ACh; 10 pg ml1 of each standard material for the
monoamines), and the peak heights of the ACh and mono-
amines in the samples were compared with those of the
standards by means of a data processor (EPC-300, Eicom).
At the end of the experiment, the rats were killed by
decapitation. Brains were quickly removed, sectioned at 50mm
thickness and placement of the microdialysis probes in the VH
was verified. The result obtained from rats in which the
dialysis membrane was not positioned exactly in the VH was
discarded.
Drugs and chemicals
TAK-147 and E2020 were obtained from Takeda Chemical
Industries Ltd, Osaka, Japan, and Eisai Co., Ltd, Tokyo,
Japan, respectively. The drugs were dissolved in MC. The
solutions were prepared freshly prior to each experiment. The
administration volume was 1ml kg1 p.o. The HPLC stan-
dards ACh perchlorate and choline were purchased from
Sigma (MO, U.S.A.). Isopropylhomocholine was from Eicom,
Japan. The following HPLC monoamine standards were used:
() epinephrine (L-adrenaline; Epi) and () NE (L-noradrena-
line) were from Nacalai tesque Inc., Kyoto, Japan. 5-HT
creatinine sulfate (3-[2-aminoethyl]-5-hydroxyindole creatinine
sulfate complex) was from Wako Pure Chemical Industries
Ltd, Osaka, Japan. The other standards were from Sigma: 3-
methoxy-4-hydroxyphenylglycol (MHPG), 3,4-dihydroxyphe-
nylacetic acid (DOPAC), normetanephrine HCl (DL-a-[amino-
methyl]-4-hydroxy-3-methoxybenzenemethanol HCl), DA HCl
(3,4-dihydroxyphenylethylamine HCl), 5-hydroxyindoleacetic
acid (5-HIAA), (7)-isoproterenol HCl (1-[30,40-dihydroxy-
phenyl]-2-isopropylaminoethanol HCl), homovanillic acid (4-
hydroxy-3-methoxyphenylacetic acid; HVA) and methoxytyr-
amine HCl (3-methoxy-4-hydroxyphenethylamine).
Statistical analysis
The study included three main groups: group 1 – received MC
(the vehicle for the drugs) and served as intact control for the
following two groups that received 2mgkg1 p.o. of either
TAK-147 (group 2) or E2020 (group 3). Statistically significant
differences in drug effects, compared to the MC, prior to (pre)
and following (post) the last dose on the 21st day, pre/post
extracellular ACh or amines levels within each group (each two
consequent postvalues reduced to one bin) and their variation
with repetition were evaluated using multifactor analysis of
variance (ANOVA) with repeated measures-unequal group
size. The treatments were regarded as between-subject factor
and the level at each point as within-subject factor. The data
for the three groups in pre- or postperiod were firstly
evaluated, and then the effect of each drug was compared to
the other groups in case any significance was detected. Post hoc
comparisons were performed by Tukey’s test whenever
ANOVA revealed a significant difference. The significance of
the effects denote the main effect of each of TAK-147 and
E2020 compared to MC, otherwise the comparison of both
drugs with each other is referred to in the text. The level of
significance was set at Po0.05. Extracellular ACh levels were
expressed as fmol 20ml1, whereas the amines as pg 30ml1. All
data are presented as means7s.e.m. The numbers of rats were
seven, 10 and eight in MC, TAK-147 and E2020 groups,
respectively, for all HPLC analysis.
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Results
Effect of TAK-147 and E2020 on ACh level in the VH
The basal level of ACh detected in the VH of intact rats prior
to the last MC administration was 92.0570.21.97 fmol 20ml1.
This level was maintained at 88.08723.76 fmol 20ml1 after
MC administration throughout analysis.
Figure 1 shows the time course of changes in the level of
ACh that were produced by 2mg kg1 TAK-147 and E2020.
TAK-147 increased the level of ACh in the VH by 114% to
197.33721.40 fmol 20ml1 on the 21st day before the last dose
(F1,15¼ 12, Po0.01). TAK-147 further increased (168%) the
ACh level after the 21st dose to 236.15729.18 fmol 20ml1
(F1,15¼ 16.29, Po0.01). However, comparison of the post-
and prevalues did not show significant change.
Although E2020 increased (46%) the ACh on the 21st day
prior to the last dose to 133.96718.03 fmol 20 ml1, the effect
did not reach significant level. However, the level of ACh
was significantly increased (80.7%) after the last dose to
159.1378.16 fmol 20ml1 (F1,13¼ 10.86, Po0.01). However,
pre-/post comparison revealed significant change only at
the last time bin, 100–120min (F1,14¼ 7.58, Po0.02). The
effect of E2020 was lower than TAK-147 by 47% prior to
(F1,16¼ 5.28, Po0.05) and by 48% after the last dose
(F1,16¼ 6.32, Po0.05). Moreover, the group repetition
interaction of TAK-147 and E2020 was different following
the last dose (F5,80¼ 2.63, Po0.05), indicating different ACh-
increasing pattern for both drugs. No significant effect of
HPLC repetition was detected for TAK-147 or E2020 within
the same group.
Effect of TAK-147 and E2020 on catecholamines level
in the VH
Effect on the NE and its metabolites The present results
showed that the level of NE in the VH of intact rats prior to
the last MC on the 21st day was 1.9270.39 pg 30 ml1. The
level of NE was maintained after MC administration
throughout analysis at 1.8170.49 pg 30ml1.
Figure 2a shows that the level of NE in TAK-147 group
(1.86770.26 pg 30 ml1) was not different from that of MC
group. However, the level of NE was significantly increased
after the last dose to 4.0771.09 pg 30ml1. This value was
higher by 125% than MC (F1,15¼ 8.22, Po0.03) and by
118% compared to prevalue within the same group
(F1,18¼ 4.44, Po0.05). On the other hand, E2020 increased
the level of NE to 3.1370.49 pg 30 ml1 prior to the last dose,
but the effect was not significant. The last dose of E2020
increased (296%) the level of NE to 7.15672.08 pg 30 ml1
(F1,13¼ 5.88, Po0.05). This level was significantly higher
than the prevalue of the same group by 129% (F1,14¼ 4.7,
Po0.05). However, the effect of E2020 was not significantly
different from TAK-147, but the dose repetition interaction
of E2020 was significantly different from MC (F5,65¼ 3.7,
Po0.01) and TAK-147 (F5,80¼ 2.98, Po0.05), indicating
that its pattern of increase is different from the other two
groups.
The present results showed that the level of Epi in the
VH was 1.9170.18 pg 30 ml1. The level of Epi was main-
tained at 1.3670.16 pg 30ml1 for 180min after MC.
Figure 2b shows that treatment with TAK-147 increased the
Epi to 8.6172.15 pg 30 ml1 (F1,15¼ 9.98, Po0.01) and
7.9671.68 pg 30ml1 (F1,15¼ 10.92, Po0.01) before and after
the last dose, respectively. The present results also showed that
the level of Epi in E2020-treated rats was also increased to
6.7370.93 pg 30 ml1 before the last dose (F1,13¼ 27.04,
Po0.01) and to 6.3870.69 pg 30ml1 after the last dose
(F1,13¼ 55.48, Po0.01). No difference was detected between
TAK-147 and E2020 groups.
The level of MHPG in the VH of rats that received MC was
11.5373.22 pg 30ml1, maintained at 10.9374.09 pg 30 ml1
for 180min following MC. TAK-147 did not significantly
increase MHPG prior to the last dose, and increased the level
to 15.8871.21 pg 30 ml1 after the last dose, but the effect
was significant only after 90min (16.3571150 pg 30 ml1;
F1,15¼ 4.94, Po0.05). On the other hand, the highest level
of MHPG was observed in the E2020 group (17.8571.47 pg
30 ml1). The effect of E2020 was significantly higher than MC
(F1,13¼ 7.4, Po0.05) and TAK-147 (F1,16¼ 6.16, Po0.05).
However, the effect of the last dose of E2020 decreased after
120min and the MHPG value was not different from either
MC or TAK-147 thereafter (Figure 2c).
The present results showed that the VH of rats that received
MC contains 3.2670.64 pg 30ml1 normetanephrine. The level
was maintained at 2.4170.46 pg 30 ml1 following MC
(Figure 2d). No significant effect was detected for either
TAK-147 or E2020 on normetanephrine.
Effect on level of DA and its metabolites level in the
VH The level of DA in the VH was 0.7770.23 pg 30 ml1,
maintained throughout the experiment period at 0.6170.13 pg
30 ml1 after MC. Figure 3a shows that TAK-147 increased
DA before the last dose to 2.6370.51 pg 30 ml1 (F1,15¼ 9.09,
Po0.01) and after the last dose to 2.3170.42 pg 30 ml1
(F1,15¼ 8.46, Po0.05). The results also showed that E2020
increased the level of DA to 2.63270.341 pg 30 ml1 on the 21st
day (F1,13¼ 20.59, Po0.01), which was further increased to
5.3970.51 pg 30ml1 after the last dose (F1,13¼ 12.76,
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Figure 1 Effect of TAK-147 (n¼ 10) and E2020 (n¼ 8) on
acetylcholine level (fmol 20 ml1) in dialysates from the VH. The
drugs were injected at 2mgkg1 p.o. for 21 days. After establish-
ment of a stable acetylcholine level (pre) on the 21st day, the last
dose of either TAK-147 or E2020 was administered (arrow) and
acetylcholine was collected and analyzed by HPLC every 20min
thereafter. Values are means7s.e.m. of each group. Data were
analyzed by ANOVA-unequal group size with repeated measures
followed by Tukey’s post hoc test. Each point is compared to MC
(n¼ 7) group. *Po0.05.
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Figure 2 Effect of TAK-147 (n¼ 10) and E2020 (n¼ 8) on NE (a),
Epi (b), 3-methoxy-4-hydroxy-phenylglycol (c) and normetanephr-
ine (d) level in dialysates from the VH. The drugs were injected at
2mg kg1 p.o. for 21 days. After establishment of a stable level (pre)
for each monoamine on the 21st day, the last dose of either TAK-
147 or E2020 was administered (arrow) and the monoamines were
collected and analyzed by HPLC every 30min thereafter. The values
are means7s.e.m. of each group. Data were analyzed by ANOVA-
unequal group size with repeated measures followed by Tukey’s post
hoc test. Each point is compared to MC (n¼ 7) group. *Po0.05.
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Figure 3 Effect of TAK-147 (n¼ 10) and E2020 (n¼ 8) on DA (a),
DOPAC (b), methoxytyramine (c) and HVA (d) level in dialysates
from the VH. *Po0.05 compared to MC (n¼ 7). Other details are as
in Figure 2.
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Po0.01). No difference was detected between pre and post
within the same group or TAK-147 and E2020.
The present results showed that the VH contains
3.3771.01 pg 30 ml1 DOPAC, maintained at 3.3970.99 pg
30 ml1 after MC on the 21st day. Although the level was
slightly elevated by both TAK-147 and E2020, statistical
analysis showed that the effects of both drugs were not
significant (Figure 3b).
The level of HVA in the VH was 4.0470.93 pg 30ml1. This
level was maintained at 3.9970.93 pg 30ml1 for 180min after
MC. The level of HVA was not significantly changed by either
TAK-147 or E2020 in spite of an apparent increase by the last
dose of TAK-147 for 30–90min (Figure 3c).
The level of 3-methoxytyramine in the VH of MC-treated
rats was 0.63570.127 pg 30ml1 prior to MC, and maintained
at 0.5170.07 pg 30ml1 for 180min thereafter. No significant
effect was produced by either TAK-147 or E2020, in spite of
the increase by TAK-147 at the 30–90min period following the
last dose (Figure 3d).
Effect of TAK-147 and E2020 on indoleamines level in
the VH The mean level of 5-HT detected in the VH was
0.7370.16 pg 30ml1 before MC, and maintained at
0.5870.07 pg 30ml1 after MC for 180min. Figure 4a shows
that TAK-147 significantly increased (F1,15¼ 6.38, Po0.05)
the level of 5-HT in the VH to 2.9470.74 pg 30 ml1. The level
of 5-HT was not increased further after the last dose, but
remained significantly higher than the corresponding level
detected in MC (F1,15¼ 4.74, Po0.05). Figure 4a also shows
that E2020 nonsignificantly increased 5-HT prior to the last
dose, but significantly increased it following the last dose to
2.4170.61 pg 30 ml1 (F1,13¼ 9.14, Po0.01). The effect is
possibly due to the increment obtained at 30–90min.
The present results also showed that the VH of control rats
contains 313.15718.42 pg 30 ml1 5-HIAA. Neither TAK-147
nor E2020 did significantly change the level of 5-HIAA
(Figure 4b).
Effect on metabolite/amine ratios The respective ratios of
DOPAC :DA, HVA :DA, MHPG :NE, 5-HIAA : 5-HT and
Epi :NE in the VH of MC-treated rats were 5.7, 6.6, 8.0, 556.1
and 1.2 prior to the last dose, and 6.4, 7.4, 8.8, 577.7 and 1.1
following the last dose. TAK-147 decreased HVA :DA to 3.5
and 3.9 prior to (Po0.03) and following (Po0.05) the last
dose. On the other hand, E2020 significantly decreased
DOPAC :DA ratio to 1.5 prior to the last dose (Po0,02).
Moreover, E2020 decreased the HVA :DA ratio to 2.9 and 3.7
prior to and following the last dose, respectively (Po0.03).
TAK-147 and E2020 decreased MHPG :NE ratio only
180min after the last dose to 5.7 and 4.0, respectively
(Po0.05). E2020 decreased 5-HIAA : 5-HT ratio only at 90–
180min following the last dose to 237 (Po0.004). The present
results revealed that prior to the last dose, TAK-147 and
E2020 increased Epi :NE ratio to 6.5 (Po0.02) and 2.7
(Po0.05), respectively. Only TAK-147 increased the ratio
after the last dose for 120min to 5.5 (Po0.05).
Discussion
The management of the AD patients encompasses chronic
prescription of the relevant drugs. AChEIs are the major drug
class used in AD treatment. In our previous study (Hatip-Al-
Khatib et al., 2004), we compared the effect of single
administration of TAK-147 and E2020, and determined the
p.o. threshold (5mgkg1) and subthreshold doses (2mg kg1)
for the effect of both drugs on ACh level in the VH. However,
we could not find in the literature any study of the effect of
chronic or subchronic TAK-147 on the levels of ACh and
monoamines in the VH. In this study, we investigated the
effect of 21-day administration (subchronic) of the subthres-
hold dose of TAK-147, compared to E2020, on the ACh and
monoamines levels in the VH.
The elevation of ACh level in the brain regions that are
associated with memory is still one of the goals in AD
treatment. The present results showed that both TAK-147 and
E2020 increased the ACh. However, the effect of TAK-147
was higher than E2020 both prior to and following the last
dose. The effect on ACh level could either be due to
modification of the drugs activity on AChE by subchronic
administration or possibly involves activities other than AChE
inhibition, since TAK-147 : E2020 potency ratio for the effect
of single administration on ACh level is 0.773 (Hatip-Al-
Khatib et al., 2004) and the AChE inhibitory levels are 12 and
6.7 nM (Ogura et al., 2000) or 26.8 and 6.3mmol kg1 (Kosasa
et al., 2000) for TAK-147 and E2020, respectively. The effect
of TAK-147 possibly does not involve inhibition of high-
affinity choline uptake or binding to nicotinic receptor,
because TAK-147 has weak or no activity in this regard (Hirai
et al., 1997). Several studies had investigated the effect of long
duration administration of E2020. Our results showed that
E2020 induced 46% increase of ACh level. The maximal
increase obtained 20min after the last dose was 97%. This rate
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Figure 4 Effect of TAK-147 (n¼ 10) and E2020 (n¼ 8) on 5-HT
(a) and 5-hydroxyindolacetic acid (b) level in dialysates from
the VH. *Po0.05 compared to MC (n¼ 7). Other details are as in
Figure 2.
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is lower than the 2100% reported for the same dose
administered for the same duration (Giacobini et al., 1996),
possibly due to the different methods of calculation or
analysis. The effect of chronic E2020 could involve 36–39%
inhibition of AChE due to complete blockade of phosphoryla-
tion (Giacobini et al., 1996; Scali et al., 2002) or involvement
of M2–M4 blockade. Moreover, the effects could also involve
increased level of hippocampal non-a7-nAChRs nicotinic ACh
receptors (Reid & Sabbagh, 2003). The present results suggest
that long-term administration of a subthreshold dose of TAK-
147 produced a greater increase of the ACh, a result different
from that of single dose.
There is an abundance of evidence indicating that mono-
amines, in addition to ACh, are also involved in the
pathogenesis of the AD and other dementic disorders. In the
AD, amyloid deposition and Alzheimer neurofibrillary tangles
occur not only in the cholinergic areas but also in the
aminergic nuclei (Yang & Schmitt, 2001). In patients with
AD, multiple changes indicate disturbed metabolism in the
ACh, DA, NE and 5-HT systems (Gottfries, 1990). It has been
reported that the monoaminergic presynaptic terminal density
decreases in the dementic diseases (Gilman et al., 2004).
Moreover, AD is a neurodegenerative disorder associated with
a decline of not only the cognitive abilities but also with
frequent manifestation of noncognitive symptoms (such as
anxiety, depression, apathy, psychosis) and other conduct
disorders that impair daily living and require treatment with
antidepressants with serotonergic and noradrenergic proper-
ties (Schrag, 2004) alone or in combination with AD drugs like
that of E2020 and sertraline combination (Finkel et al., 2004).
In addition to the cognition, the noncognitive aspects of
dementia, however, are also linked to 5-HT and DA rather
than ACh, because those neurotransmitter systems most
directly influence mood, emotional balance and psychosis,
indicating a role of the aminergic system directly or by
modulating the cholinergic activity. Moreover, it has been
proposed that impairment of the cholinergic activity alone may
not be sufficient to cause the marked changes in cognition and
cortical activity that are typical for AD. In rats, lowered 5-HT
or NE activity alone often produces only minor impairments in
learning/memory tasks and does not block EEG activation.
The same monoaminergic deficits, however, result in severe
behavioral impairments, and reduce or abolish EEG activation
when they occur in a brain already affected by lowered
cholinergic activity. On the other hand, combined cholinergic–
monoaminergic stimulation had been reported to be more
effective in reversing behavioral impairments and EEG
slowing in rats with multiple neurotransmitter deficiencies
than cholinergic enhancement alone (Dringenberg, 2000).
Accordingly, the effects of the AD drugs on the aminergic
systems in addition to that on the cholinergic system are of
value in affecting multiple deficits forming the hallmark of the
AD pathology or appear concurrently with it.
Of the monoamines, NE activity is important for neuropro-
tection, and its deficiency could be involved in the mechanisms
predisposing to the AD, especially in depressed AD patients
(Hoogendijk et al., 1999). In the AD, there is a significant
reduction in NE and HVA levels in the cerebrospinal fluid
(Martignoni et al., 1991) and neuronal loss in the locus
ceruleus. The reduction in NE concentration is correlated with
cognitive impairment (Matthews et al., 2002). Inflammation
and reduced forebrain NE are features of the AD that may
interact to contribute to the degeneration of specific neural
systems. It has been reported that NE deficiency eventually
augments inflammatory responses to Abeta (Heneka et al.,
2002). Experimental evidence suggests that cortical NE
depletion due to degeneration of the locus ceruleus, a
pathological hallmark of the AD, plays a permissive role in
the development of inflammation in the AD (Galea et al.,
2003). This is because NE decreases the inflammatory reaction
observed in the AD by increasing peroxisome proliferator-
activated receptor gamma (Klotz et al., 2003) and reducing
cytokine expression in microglial, astroglial and brain en-
dothelial cells (Feinstein et al., 2002). Moreover, ACh can
stimulate the hippocampal NA release via muscarinic receptors
(Kiss et al., 1999). The present results reveal that the VH
content of NE is greater than DA and 5-H. Moreover, our
results showed that TAK-147 and E2020 significantly in-
creased NE after the last dose, a result in line with that
reported for neostigmine (Kiss et al., 1999), suggesting a
possible trigger of NE turnover rate and release by the last
dose on multiple dosing. In addition to the ACh, TAK-147
activates the monoaminergic systems (Ishihara et al., 2000),
and inhibits ligand binding at a-1, a-2 receptors (Hirai et al.,
1997). The NE-increasing effect of TAK-147 could be via
acceleration of the turnover rate and stimulation of hippo-
campal M1 and M2 muscarinic receptors (Hirai et al., 1997).
The effect of at least E2020 on the NE is a central one because
E2020 does not change the plasma concentration of NE
(Masuda & Kawamura, 2003), and could be attributed to an
increase of hippocampal non-a7 nAChR (Rogers & Hagan,
2001) leading to NE release (Dajas-Bailador et al., 2003). The
increase by E2020 of NE agrees with the results reported for
E2020 (Giacobini et al., 1996). However, the percentage
increase of NE reported in this study produced by the last
dose of E2020 (296%) is higher than the 100% NE increase
reported for single subcutaneous 2mgkg1 E2020 (Giacobini
et al., 1996). This difference is possibly due to the multiple oral
administration of E2020 in our study compared to single
subcutaneous route in the latter study, and could indicate
increase of the effect by repetition of the doses. Moreover, the
present results revealed that E2020-induced NE release is
higher than that produced by TAK-147 prior to (63% vs no
increase) and following the last dose (296 vs 125% increase).
Moreover, the E2020-produced NE increase at the peak effect
time 150min after the last dose (304%) is also greater than
TAK-147 (82%).
Epi is another monoamine that could also be involved in the
AD, as Epi system interacts with the cholinergic one. It has
been reported that stimulation of the hippocampal cholinergic
system results in the elevation of plasma catecholamines and
glucose in rats. Moreover, the plasma level of Epi during a
fasting state in patients with dementia of Alzheimer type is
significantly lower than that of nondementic subjects (Ume-
gaki et al., 2000). The present results showed that the level of
Epi in the VH is close to that detected for NE, and the mean
Epi :NE ratio is one in MC group. TAK-147 and E2020
increased the Epi level. The effect of E2020 on Epi is probably
produced centrally, because E2020 does not change the plasma
concentration of Epi (Masuda & Kawamura, 2003). More-
over, our results showed that TAK-147 increased Epi :NE
ratio more than E2020. The elevation of Epi and Epi :NE ratio
by TAK-147 and E2020 could be important in the activity of
both drug.
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The dopaminergic activity is another candidate involved in
the memory regulation. It has been reported that the marginal
division (at the caudomedial border of the neostriatum in the
brain of the rat, and links the limbic system and the basal
nucleus of Meynert) plays an important role in the execution
of digital working memory, and involved in AD pathology
(Lehericy et al., 1994; Shu et al., 2002). Moreover, the
dopaminergic activity is modified by the ACh. It has been
reported that the ACh and DA act convergently on the nucleus
accumbens circuit (Hikida et al., 2003). On the other hand,
AChEIs are effective in the treatment of disorders other than
the AD. The AChEIs have been reported to suppress both
cocaine- and morphine-induced conditioned place preference
and block the induction and persistence of cocaine-evoked
hyperlocomotion (Hikida et al., 2003). Moreover, AChEIs are
effective in treatment of attention-deficit/hyperactivity dis-
order (Spencer & Biederman, 2002) and management of
symptoms of dementia accompanying patients with comorbid
schizophrenia and dementia (Stryjer et al., 2003). In the
neostriatum (caudate nucleus), loss of DA and increased
HVA :DA ratio is correlated with the reduction in substantia
nigra neurons in Lewy body dementia but not Parkinson’s
disease (Perry et al., 1993). In this study, TAK-147 increased
DA to a similar extent produced by E2020. The effect of TAK-
147 could mainly be due to inhibition of DA reuptake and/or
acceleration of DA turnover, but not to activity on DA1 or
DA2 receptors (Hirai et al., 1997). On the other hand, the
effect of E2020 on DA is due to increase of DA release (Zhang
et al., 2004). The dopaminergic properties of both TAK-147
and E2020 may be useful in the treatment of disorders
involving dopaminergic systems in specific patients subgroup.
The serotonergic system, directly or indirectly, could affect
the mental state. It has been reported that the cholinergic and
serotonergic systems are involved in maintaining brain arousal
(Abe et al., 2003). The serotonergic raphe nuclei with
ascending projections to the forebrain is involved in fronto-
temporal dementia both with and without motor neuron
disease (Yang & Schmitt, 2001). Moreover, it has been
reported that blockade of 5-HT(1A) receptors attenuates
the anterograde amnesia produced by muscarinic-receptor
blockade (Misane & Ogren, 2003), and may be useful in
the treatment of some aspects of attentional dysfunction in the
AD (Balducci et al., 2003). 5-HT6 antagonism improves
retention of water maze task in the rat (Rogers & Hagan,
2001). In patients with AD, 5-HT and melatonin levels are
decreased in the cerebrospinal fluid during the progression of
the AD neuropathology (Xu et al., 2002), and 5-HIAA is
reduced in the temporal cortex (Perry et al., 1993). In
this study, TAK-147 increased 5-HT, but nonsignificantly
increased 5-HIAA, indicating that TAK-147 accelerates
5-HT turnover rate, but at an extent exceeding its metabolism.
The effect of TAK-147 could also be due to inhibition of
uptake of 5-HT (Hirai et al., 1997). We do not think the effect
of TAK-147 is produced on 5-HT1 receptor because TAK-147
displays only weak activity on these receptors (Hirai et al.,
1997). On the other hand, E2020 increased the 5-HT only for
90min after the last dose, suggesting a lesser effect of E2020 on
the 5-HT than TAK-147. The dual effect, especially by TAK-
147, on 5-HT and NE in addition to the DA could be of great
value in the treatment of diseases where these amines are
decreased, like AD (Abe et al., 2003) and diffuse Lewy body
(Ohara et al., 1998).
The present results showed a higher level of MHPG (NE),
DOPAC, HVA (DA) and 5-HIAA (5-HT) than the corre-
sponding amine, indicating a high metabolic rate for these
amines in the VH of intact rats that received MC. Moreover,
the results also showed high metabolic rate of NE (high
MHPG level and higher mean MHPG :NE ratio) that is higher
than another catecholamine, that is, DA (DOPAC :DA
and HVA :DA). However, the results also showed that the
5-HIAA : 5-HT ratio is greater than the ratio values for
catecholamines, indicating high metabolic rate of 5-HT in the
VH. The metabolism of various monoamines is impaired to
a different extent according to the type of dementia. 5-HIAA
and HVA were proposed important in certain circadian
symptoms, for example, the changes in sleep/wake rhythms
that are rather often observed in dementia (Wallin et al.,
1991). Moreover, 5-HIAA and HVA are decreased in the
patients with vascular dementia and AD (Parnetti et al., 1992;
Sjogren et al., 1998). In this study, TAK-147 and E2020
increased the level of the metabolites (especially MHPG).
This activity may add to the aminergic effects of TAK-147
and E2020.
In the AD, not only an impairment of the monoaminergic
systems but an overactivity of cerebral monoamineoxidase B
has frequently been reported as well (Martignoni et al., 1991).
In patients with Lewy body dementia, there is lower neuron
counts, loss of DA and increased HVA :DA ratio in the
neostriatum, possibly due to higher turnover ratios in the
surviving neurons. Moreover, it has been reported that a
subgroup of the Lewy body dementia patients experiencing
hallucinations could be distinguished from the other categories
by an increase in the 5-HIAA : 5-HT and serotonergic : choli-
nergic ratio measured in the frontal cortex (Perry et al., 1993).
Moreover, it has been reported that 5-HT (precursor of
melatonin) is stepwise depleted during the course of the AD, as
indicated by the upregulated monoamine oxidase A mRNA
activity and increased 5-HIAA : 5-HT ratio (Wu et al., 2003).
In this study, TAK-147 decreased mainly the HVA :DA ratio.
E2020 additionally decreased DOPAC :DA and 5-HIAA :
5-HT ratio. Both drugs decreased MHPG :NE ratio only at
180min. The reduction in the ratio of monoamine metabolite
to the relevant transmitter and subsequent reduction of free
radical production by either TAK-147 or E2020 could be
involved in the neuroprotective activity displayed by both
drugs, treatment of cohort psychiatric disorders and may
suggest extension of the therapeutic property of both drugs to
include dementia other than the AD, for example, Lewy body
dementia. The present results showed that Epi :NE ratio was
increased by both drugs, especially the TAK-147. The
implication of this effect in the clinical effects of TAK-147
and E2020, if any, remains to be clarified.
In conclusion, the present results showed that 21-day
treatment with 2mgkg1 p.o. TAK-147 increased ACh, Epi
and DA. TAK-147 additionally increased 5-HT, whereas
E2020 increased MHPG. The last dose triggered the NE-
increasing effect of both drugs, and 5-HT-increasing effect of
E2020 on 5-HT. Moreover, TAK-147 and E2020 decreased
HVA :DA ratio, but increased Epi :NE ratio. E2020 addi-
tionally decreased DOPAC :DA prior to, and 5-HIAA : 5-HT
ratio following, the last dose. TAK-147 could differentially
be more useful in cases where ACh or 5-HT are reduced,
whereas E2020 in cases involving reduced MHPG. Both
drugs could be of value in cases involving reduced DA, NE
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and Epi. Stimulation of monoaminergic activity in conjunc-
tion with the AChE activity may provide an effective
treatment option for AD and the accompanying psychiatric
disorders.
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